Item 9 Labs Corp.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Jeffrey I. Rassas
- Full Time Employees
- 97
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Address
- 2727 North 3rd Street Phoenix AZ United States of America 85004
- IPO Date
- Jan 25, 2012
- CIK
- 0001500123
- Website
- item9labscorp.com
- Similar Companies
- Business
- Item 9 Labs Corp. (OTCQX: INLB) operates as a vertically integrated cannabis company and dispensary franchisor primarily in the United States, producing and distributing premium cannabis and cannabis-derived products through its Item 9 Labs brand as well as franchising medical and adult-use dispensaries under the Unity Rd. retail brand. The company offers an extensive portfolio of core products including flower across approximately 75 active strains; concentrates such as live resin sugar, live resin badder, and crumble; distillates; vaporizer cartridges comprising more than 150 differentiated options; pre-rolls; and proprietary hardware like Orion vape technologies and Orion 710, which it sells through licensed dispensaries mainly to consumers in Arizona. Item 9 Labs Corp., founded in 2010 and headquartered in Phoenix, Arizona, with cultivation and production facilities including in Casa Grande, Arizona, conducts operations through its two primary segments of cultivation/production and franchising, targeting medical and recreational cannabis markets with a workforce of around 101 employees. In recent developments, the company executed a major restructuring in May 2023 that reduced annual operating expenses by more than $3.5 million, streamlined its board and executive team including the appointment of Mike Weinberger as CEO, and shifted focus toward capital-light expansion of the Item 9 Labs brand into new U.S. states while pursuing debt restructuring to enhance its balance sheet and return to profitability following positive adjusted EBITDA in its fiscal second quarter 2023. Item 9 Labs Corp. also retained Sharp Capital Advisors in late 2023 to facilitate a potential sale of the business amid ongoing capital market challenges in the cannabis sector. Earlier, it cancelled its planned $12.8 million acquisition of Canadian franchisor Sessions Cannabis in May 2023 after securing financing, reflecting adaptive strategic shifts in its international growth plans.
Item 9 Labs Surpasses 30 Podium Placements With 2022 Fall Errl Cup Wins
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2022 Results - Earnings Call Transcript
Item 9 Labs Corp. (INLB) Reports Q3 Loss, Misses Revenue Estimates
Item 9 Labs Corp. to Host Third Quarter Fiscal Year 2022 Earnings Call on August 16 at 8:30 a.m. ET
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q2 2022 Results - Earnings Call Transcript
Item 9 Labs Corp. (INLB) Reports Q2 Loss, Lags Revenue Estimates
Item 9 Labs Corp. to Present at Leading Investor Conferences in April
Unity Rd.'s Chief Franchise Officer to Present at International Franchise Association's 2022 Convention
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q1 2022 Results - Earnings Call Transcript
Unity Rd.'s VP of Communications to Present at YoungConference
Item 9 Labs Corp.'s (INLB) CEO Andrew Bowden on Q4 2021 Results - Earnings Call Transcript
Item 9 Labs Corp. to Acquire Colorado Dispensary, Kickstarts National Acquisition Growth Plan
Item 9 Labs Corp. Bolsters Marketing Team with Multiple Key Hires
Unity Rd. Vice President and Franchise Partner to Present at MLive Cannabis Insights Event on October 7
Item 9 Labs Corp. to Present at A.G.P.'s Virtual Fall Consumer Cannabis Conference October 5
Unity Rd. Inks Deals for New Jersey and Virginia; Announces Maine Expansion
Item 9 Labs Corp.'s Dispensary Franchise Expands NE Footprint into 2 New States
Item 9 Labs Corp. Secures $19 Million Construction-Financing Loan with Pelorus Equity Group for Expansion of Cultivation & Lab Sites in Arizona & Nevada
Item 9 Labs' Cannabis Cup Win Marks 9 Top Podium Placements
Item 9 Labs Corp. (INLB) CEO Andrew Bowden on Q3 2021 Results - Earnings Call Transcript